A study published in the European Journal of Cancer has found that the cancer drug viagra could help treat patients who suffer from low metabolism, a condition known as insulin resistance.
According to the researchers, the drug, known as rosiglitazone, has been used for decades to treat type 2 diabetes and is also used to treat people with metabolic syndrome, a cluster of related conditions that can be caused by excess insulin.
Researchers from the University of Exeter in England, the University College London and the University Hospitals of Manchester in the UK conducted a controlled trial of the drug in two groups of people with diabetes.
The study, which involved 14 patients with type 2, 14 patients without diabetes and 14 healthy volunteers, looked at how the drug affects blood sugar levels.
It found that in the treatment groups, when people took the drug they lost about 1.5 kg compared to 1.3 kg in the placebo group.
The researchers believe that the drug may help people who are insulin resistant because they are unable to control their blood sugar level, which may make them feel worse.
The drug was first developed in the 1960s as a treatment for patients with heart disease.
In the 1970s it was used to help people with high blood pressure and heart disease to control it, but it was abandoned for obesity treatment.
Researchers say it may also help people suffering from metabolic syndrome because of their low metabolic rate.
They say that people who have metabolic syndrome tend to have higher cholesterol levels and are also more likely to smoke, which is linked to a higher risk of heart disease and stroke.
The trial is a follow-up to a study done in 2012, which also found that it reduced blood sugar by up to 25 per cent when people with insulin resistance took it.
The team behind the study say that the results of this new study show that it may help the people who suffer insulin resistance, because they can improve their blood sugars by lowering the amount of fat they store in their bodies.
“The patients in the rosigo study lost an average of 2.4 kg when taking rosigeldin, compared to an average loss of 2 kg in placebo-treated patients,” they said in a statement.
“This means that taking rozeglutide may help to decrease the risk of type 2 diabetics developing type 2 and even type 3 diabetes.”
The study was carried out in a double-blind, placebo-controlled study.
Researchers also used a drug called dutasteride, which can help with weight loss and diabetes.
A study published last month found that patients who were on a treatment called metformin had lower blood pressure when taking the drug.
Researchers said that it was also possible that people with type 1 diabetes, who are unable or unwilling to control blood sugar, could benefit from taking the drugs, because the medications help regulate blood sugar.
“Type 1 diabetes patients are at higher risk for type 2 metabolic syndrome,” they added.
“There is a potential for these patients to benefit from a combination of roziglitacaine and metformins.”
The researchers also found an improvement in the way that the treatment was working in patients who had type 1 metabolic syndrome.